







COVAXIN[®]

PUBLICATIONS

Sr. No	Published	Title	Journal
1.	Phase 1 Human Clinical Trial https://doi.org/10.1016/S1473-3099(20)30942-7	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial	THE LANCET Infectious Diseases
2.	Hamster Efficacy Study https://doi.org/10.1016/j.isci.2021.102054	Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model	
3.	Non-Human Primate Efficacy Study https://doi.org/10.1038/s41467-021-21639-w	Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques	nature communications
4.	Phase 2 Human Clinical Trial https://doi.org/10.1016/S1473-3099(21)00070-0	Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report	THE LANCET Infectious Diseases
5.	Preclinical Safety and Immunogenicity https://doi.org/10.1016/j.isci.2021.102298	Th1 Skewed immune response of Whole Virion Inactivated SARS-CoV-2 Vaccine and its safety evaluation	
6.	Neutralization of UK Variant (B.1.1.7) https://doi.org/10.1093/jtm/taab051	Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2	
7.	Neutralization of Brazil variant of concern P2 (B.1.1.28) https://doi.org/10.1093/jtm/taab077	Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine	
8.	Neutralization of South Africa Variant (B.1.351) and Delta Variant (B.1.617.2) https://doi.org/10.1101/2021.06.05.447177	Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccines of BBV152	
9.	Neutralization of Double mutant (B.1.617) https://doi.org/10.1093/cid/ciab411	Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccines	Clinical Infectious Diseases

10.	Phase 3 Human Clinical Trial http://www.thelancet.com/journals/lanct/article/PIIS0140-6736(21)02000-6/fulltext	Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomized, double-blind, controlled, phase 3 trial	THE LANCET
11.	Booster Dose: COVAXIN® (BBV152) Phase 2 Trial https://www.medrxiv.org/content/10.1101/2022.01.05.22268777v1	Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial	 THE PREPRINT SERVER FOR HEALTH SCIENCES
12.	COVAXIN® efficacy in Hamsters against Delta and Omicron variants https://www.biorxiv.org/content/10.1101/2022.06.14.496021v1.full.pdf	Protective efficacy of COVAXIN® against Delta and Omicron variants in hamster model	
13.	T- Cell response https://www.nature.com/articles/s41564-022-01161-5	Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern	
14.	Paediatric study 2 to 18 years https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00307-3/fulltext	Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (BBV152) in children from 2 to 18 years of age: an open-label, age-de-escalation phase 2/3 study	THE LANCET Infectious Diseases